Gilead Sciences acquires Tubulis for $5bn

Gilead Sciences has concluded its acquisition of Germany-based biotechnology company Tubulis in a transaction valued at up to $5bn. Gilead acquired all outstanding equity of Tubulis for $3.15bn upfront, plus up to $1.85bn in milestone payments. The acquisition provides Gilead access to advanced ADC technologies. Credit: Melnikov Dmitriy / Shutterstock.com. Gilead Sciences has concluded its acquisition of Tubulis, a Germany-based biotechnology company developing next-generation antibody-drug conjugates (ADCs), in a transaction valued at up to $5bn. First announced last month, the move aims to advance Gilead’s oncology portfolio. Immuno-oncology (IO) Thematic Intelligence Reports Chronic Myeloid Leukemia (CML): Global Drug Forecast…

Salong Debbarma · 2026-05-22

Gilead Sciences has concluded its acquisition of Germany-based biotechnology company Tubulis in a transaction valued at up to $5bn.

Source: Pharmaceutical Technology